Article
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Leukemia research - 1 Apr 2018
Advani Anjali S, Li Hongli, Michaelis Laura C, Medeiros Bruno C, Liedtke Michaela, List Alan F, O'Dwyer Kristen, Othus Megan, Erba Harry P, Appelbaum Frederick R
Abstract excerpt
Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukemia (AML) blasts to chemotherapy. A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count recovery (CRi)]. However, this population was a favorable risk group as eligible patients had to have a CR/CRi...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.